TEVA - CIK 0000818686
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported net income of $1.41B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $1.41B | +186.0% |
| FY 2024 | -$1.64B | -193.2% |
| FY 2023 | -$559.00M | +77.1% |
| FY 2022 | -$2.45B | -686.6% |
| FY 2021 | $417.00M | +110.5% |
| FY 2020 | -$3.99B | -299.4% |
| FY 2019 | -$999.00M | +53.5% |
| FY 2018 | -$2.15B | +86.8% |
| FY 2017 |
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported net income of $1.41B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, TEVA PHARMACEUTICAL INDUSTRIES LTD's net income declined from $2.76B to $1.41B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$16.27B |
| -5043.8% |
| FY 2016 | $329.00M | -79.3% |
| FY 2015 | $1.59B | -48.0% |
| FY 2014 | $3.06B | +140.7% |
| FY 2013 | $1.27B | -35.4% |
| FY 2012 | $1.96B | -28.9% |
| FY 2011 | $2.76B | - |